Drugs / BNT162b2SA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04368728 | Apr 2020 → Feb 2023 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2SA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04368728 ↗ |
| Known as | BNT162b2s01 | “The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a...” NCT04368728 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT04368728 ↗ |